Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Warm Homes for Elder New Zealanders (WHEZ)

15 de junio de 2015 actualizado por: Philippa Howden-Chapman, University of Otago

Warm Homes for Elder New Zealanders: a Community Trial of People With COPD

Aim

The purpose of this study is to evaluate whether fuel subsidies reduce exacerbations of COPD among people aged over 55, and therefore whether providing such subsidies is a cost-beneficial policy initiative.

The Warm Homes for Elder New Zealanders Study enrolled community-dwelling people aged over 55 with moderate or worse COPD. Prior to the study commencing the houses were insulated (if feasible, & the house-owner agreed). Data were collected on the health and energy use of the participants.

The households randomly assigned to the "early" intervention group had a subsidy to their power account their first winter in the study. The subsidy was the intervention and was designed to enable the participants, if they chose to do so, to keep their house warmer during the winter.

Descripción general del estudio

Descripción detallada

Warm Homes for Elder New Zealanders (WHEZ)

Background Although there has been considerable recent work on the prevention, management and causes of Chronic Obstructive Pulmonary Disease (COPD), the contribution of housing has not been well researched. This is despite the socio-economic patterning of COPD (Maori women have the highest rate of COPD that has been recorded for any group of women), and the relationship between socio-economic deprivation and housing conditions.

It is likely that improved heating would reduce exacerbations of COPD as:

  • COPD patients with the most advanced disease tend to be older people who often live on a fixed income and may be unable to afford adequate heating
  • There is a high excess of winter hospitalisations in COPD patients indicating COPD exacerbations may be triggered by cold conditions.
  • About one third of exacerbations of COPD are triggered by respiratory infections.
  • The Housing, Insulation and Health Study demonstrated a reduction in self-reported respiratory disease after houses were insulated. Therefore improving the heating in households with a COPD patient may reduce respiratory infections and this in turn would reduce the number and severity of exacerbations.

The percentage of people over 65 in New Zealand will increase from 12% to 22% over the next 25 years. Therefore it will become increasingly important to find cost-effective ways of reducing the morbidity of the older age group. As COPD is a significant cause of morbidity amongst older people, this study investigates a potentially cost effective intervention to reduce both the likelihood of expensive hospital stays and improve the quality of life for older people.

Aim To evaluate whether fuel subsidies reduce exacerbations of COPD among people aged over 55, and therefore whether providing such subsidies is a cost-beneficial policy initiative.

Potential Benefits The potential benefits of the study include reducing the burden of disease. The patients and their caregivers may experience improved quality of life. Hospitals may experience fewer patients requiring treatment during the winter. A cost-benefit analysis will quantify the benefits.

Tipo de estudio

Intervencionista

Inscripción (Actual)

522

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Christchurch, Nueva Zelanda
        • Christchurch
      • Wanganui, Nueva Zelanda
        • Wanganui / Manawatu
      • Wellington, Nueva Zelanda
        • Wellington / Hutt/ Porirua

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

55 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Post Bronchodilator FEV1/FVC ratio < Lower Limit of Normal (NHanesIII)
  • Post Bronchodilator FEV1 < 80% of the predicted FEV1 (NHanesIII)

OR - In the last three years either went to hospital for their COPD or took antibiotics/steriods for their COPD

Exclusion Criteria:

  • Not planning to stay in the same dwelling until the end of the study
  • Does not want to take part in research
  • Unwilling to answer inclusion questionnaire
  • Unable to communicate effectively

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Voucher
Receive the intervention ("Energy Voucher") the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
Otro: Control
Receive the intervention the second winter enrolled in the study (thus "No intervention : control arm"). The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
Do not receive the money or pamphlet in the initial study year

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Moderate or severe exacerbations of COPD during winter for which hospitalisation, systemic corticosteroids and/or antibiotics are required to treat the exacerbation
Periodo de tiempo: Four months
Four months

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Severe exacerbations of COPD during winter for which hospitalisation is required to treat the exacerbation
Periodo de tiempo: Four months
Four months
Moderate exacerbations of COPD during winter; which will be defined as requiring treatment with systemic corticosteroids and/or antibiotics
Periodo de tiempo: Four months
Four months
All-cause hospitalisation during winter
Periodo de tiempo: Four months
Four months
Temperature in the living and bedrooms during winter
Periodo de tiempo: Four months
Four months
Electricity usage during winter
Periodo de tiempo: Four months
Four months
Costs to health care system of index participant during winter
Periodo de tiempo: Four months
Four months
Self-reported quality of life for index participant during winter
Periodo de tiempo: Four months
Four months
Respiratory health of other people living in household during winter
Periodo de tiempo: Four months
Four months
Any changes in index participant baseline lung function
Periodo de tiempo: course of study ( up to 18 months)
course of study ( up to 18 months)
Study withdrawals due to death or greater dependency
Periodo de tiempo: course of study (up to 18 months)
course of study (up to 18 months)
Support person burden
Periodo de tiempo: course of study (up to 18 months)
course of study (up to 18 months)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Philippa L Howden-Chapman, PhD, University of Otago

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de abril de 2009

Finalización primaria (Actual)

1 de febrero de 2013

Finalización del estudio (Actual)

1 de febrero de 2013

Fechas de registro del estudio

Enviado por primera vez

2 de agosto de 2011

Primero enviado que cumplió con los criterios de control de calidad

20 de junio de 2012

Publicado por primera vez (Estimar)

25 de junio de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

17 de junio de 2015

Última actualización enviada que cumplió con los criterios de control de calidad

15 de junio de 2015

Última verificación

1 de junio de 2015

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • HRC08/072AR

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir